A California biotechnology company has achieved a historic regulatory milestone after the United States Food and Drug Administration cleared a first-of-its-kind immune-cell treatment aimed at protecting blood cancer patients from one of the most feared consequences of donor stem cell transplantation. On July 1, 2026, the FDA approved Tregzi — developed by Orca Biosystems, Inc. — as the first regulatory T cell–based immunotherapy authorized to improve chronic graft-versus-host disease (GVHD)–free survival in adult patients undergoing allogeneic stem cell transplants.
A Long-Standing Problem in Transplant Medicine
For decades, physicians treating blood cancers such as acute leukemia and myelodysplastic syndrome have relied on allogeneic hematopoietic stem cell transplants — procedures that infuse blood-forming cells from a closely matched donor into the patient's body. While these transplants can be curative, they carry a serious and persistent risk: the donor's immune cells may identify the recipient's tissues as foreign and begin attacking them, a condition known as chronic GVHD.
Chronic GVHD can drastically reduce both quality of life and long-term survival, and standard transplant protocols have historically offered limited success in preventing it. The FDA's approval of Tregzi directly addresses this gap, according to agency officials.
The Science Behind Tregzi
Tregzi is not a single-cell product. According to FDA prescribing information, the therapy is constructed from three distinct components drawn from a donor's blood: purified blood-forming stem and progenitor cells, regulatory T cells (Treg cells), and conventional T cells. All donor material must come from an 8/8 HLA-matched related or unrelated donor — meaning the donor and recipient share identical immune-system markers across eight critical genetic loci.
The therapy is given to patients after they have completed chemotherapy conditioning — the preparatory regimen that clears the body to receive new cells. Treg cells serve as natural regulators of immune activity, helping the body distinguish between its own tissues and genuine threats. By incorporating these cells into the transplant product, Tregzi attempts to rebuild the patient's immune system while simultaneously training it to tolerate the recipient's body rather than attacking it.
Clinical Evidence: The PRECISION-T Trial
The FDA's decision was supported by data from the PRECISION-T trial, a randomized controlled study enrolling 187 adult patients diagnosed with blood cancers including acute leukemia and myelodysplastic syndrome, the FDA reported. Trial participants were assigned to receive either Tregzi or a conventional stem cell transplant.
The study's primary endpoint measured chronic GVHD–free survival, which the FDA defined as the length of time following transplantation before a patient either died from any cause or experienced the first onset of moderate or severe chronic GVHD within a two-year window.
Results at the one-year follow-up were striking. Among patients in the Tregzi arm, 78 percent achieved chronic GVHD–free survival, compared with just 38.4 percent in the standard transplant group. When accounting for death as a competing risk, only 12.6 percent of Tregzi recipients developed serious chronic GVHD within one year — against 44 percent among those who received a conventional transplant. Based on this evidence, the FDA concluded that the benefits of Tregzi clearly outweigh its associated risks.
Safety Observations During the Trial
According to FDA prescribing information, the side effects observed in trial participants were largely consistent with those expected during any stem cell transplant procedure, with infections representing the most frequently reported adverse event. Importantly, the trial recorded no severe infusion reactions during Tregzi administration. Additionally, no cases of graft failure — a serious complication where transplanted cells fail to engraft and begin functioning — were documented throughout the study period. Orca Biosystems and the FDA advise clinicians and patients to consult the complete prescribing information for full safety and dosing guidance.
What the FDA's Acting Director Said
Karim Mikhail, Acting Director of the FDA Center for Biologics Evaluation and Research, described the approval as a meaningful step forward for patients who face serious risks even after a successful transplant clears their original cancer. Mikhail stated that chronic GVHD has long been one of the most feared and hardest-to-prevent complications for blood cancer patients requiring stem cell transplantation, and said the approval reflects both a new clinical approach and the broader promise of cellular therapy to deliver tangible benefit to patients.
Special Regulatory Designations
During its development pathway, Tregzi received two distinct FDA designations that reflect the agency's recognition of both the rarity of the target population and the novelty of the therapeutic approach. The FDA granted the product Orphan Drug designation — a status conferred on therapies targeting rare diseases that provides certain regulatory incentives to encourage development — as well as Regenerative Medicine Advanced Therapy (RMAT) designation, which is reserved for cell and gene therapies demonstrating early clinical evidence of benefit for serious conditions, according to the FDA.
Together, these designations underscore the agency's view that blood cancer patients undergoing allogeneic transplants represent a medically underserved population with significant unmet needs, particularly around the prevention of transplant-related immune complications.
By the Numbers
- 187 — adult blood cancer patients enrolled in the PRECISION-T randomized trial
- 78% — proportion of Tregzi patients who achieved chronic GVHD–free survival at one year
- 38.4% — proportion of standard-transplant patients who achieved GVHD–free survival at one year
- 12.6% — Tregzi patients who developed serious chronic GVHD within one year
- 44% — standard-transplant patients who developed serious chronic GVHD within one year
- 8/8 — HLA genetic loci required to match between donor and recipient for Tregzi eligibility
- 2 — special FDA designations granted to Tregzi: Orphan Drug and Regenerative Medicine Advanced Therapy
Why This Matters
The FDA's clearance of Tregzi marks the first time any regulatory T cell–based therapy has been authorized by a major drug authority to address chronic GVHD, a complication that has resisted reliable prevention under standard transplant protocols for generations. Data from the PRECISION-T trial show that Tregzi more than doubled the one-year rate of GVHD-free survival — from 38.4 percent under conventional treatment to 78 percent — while reducing the incidence of serious chronic GVHD from 44 percent to 12.6 percent. For adults living with acute leukemia, myelodysplastic syndrome, and related blood cancers who have few protective options after transplantation, the availability of Tregzi represents a clinically significant advance that could alter long-term survival and quality-of-life outcomes.
Source: Originally reported by FDA.gov / Orca Biosystems press materials